Diligence memo · auto-generated · as of July 2, 2026
Ten63 Therapeutics, Inc.
Ten63 Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ten63 Therapeutics, Inc. operates in Pharma, based in DURHAM.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ten63 Therapeutics, Inc. has raised $2.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.1M on 2021-01-06.
Most recent recorded round closed around 2021-01-06.
Valuation (modeled)modeled
Provath models Ten63 Therapeutics, Inc. at approximately $63M (range $1.6M–$427M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.10× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.5 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 44% of Pharma peers (310 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: Zoo Pharma Dynamics Inc., Pharma-Labs Finance LLC, FSD Pharma Inc., Deepbiome Therapeutics, Inc., Pykus Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.